# Iruplinalkib

Source: https://onco.cc/drugs/iruplinalkib/  
OnCo record `iruplinalkib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.

## Summary

Iruplinalkib (WX-0593) was developed by Qilu Pharmaceutical in Jinan. The NMPA approved it in June 2023 for locally advanced or metastatic ALK-positive non-small-cell lung cancer that had progressed on or was intolerant to crizotinib, and in 2024 extended the approval to first-line use after the INSPIRE phase 3 trial showed longer progression-free survival than crizotinib.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Qixinke
- Tags: china; nmpa-approved
- Code: WX-0593
- Modality: Oral ALK and ROS1 tyrosine kinase inhibitor
- Mechanism: Blocks the ALK fusion kinase that drives about five percent of non-small-cell lung cancers, including resistance mutations that stop first-generation inhibitors.
- Approvals: CN 2023: ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024

## Sources

- ClinicalTrials.gov: trials of iruplinalkib: https://clinicaltrials.gov/search?intr=WX-0593

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [ALK](https://onco.cc/targets/alk/), [ROS1](https://onco.cc/targets/ros1/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/iruplinalkib.json